


I hereby certify that this correspondence is being deposited with the United States Postal Service as first-class mail in an envelope addressed to: Commissioner for Patents, Washington, D.C. 20231 on this 7th day of February, 2002.

By

  
signature of person mailing)  
ROY F. WALDRON

(Typed or printed name of person)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF: R. S. Obach :

APPLICATION NO.: 09/528,798 :

Examiner: S. Jiang

FILING DATE: March 21, 2000 :

Group Art Unit: 1617

TITLE: USE OF CYP2D6 INHIBITORS IN  
COMBINATION THERAPIES :Commissioner for Patents  
Washington, D.C. 20231Sir: RESPONSE AND AMENDMENT UNDER 37 C.F.R. § 1.111

This is responsive to the Examiner's First Office Action mailed August 14, 2001, a Response to which was due on November 14, 2001. Applicant has submitted herewith a Petition for Extension of Time to extend the time for response by three months up to and including February 14, 2002 and paid the requisite fee. Accordingly, this response is timely. Please amend the application as follows:

IN THE CLAIMS

Cancel claims 2-5, 7-10, 12-13 and 14-22. Amend claim 1. Marked up copy in Appendix.

CLEAN COPY - ENTER

1. (Amended) A method of administering a drug for which the major clearance mechanism in humans is CYP2D6 mediated oxidative biotransformation and that is a neurokinin-1 (NK-1) receptor antagonist containing a primary, secondary or tertiary alkylamine moiety, or a pharmaceutically acceptable salt thereof, in combination with a CYP2D6 inhibitor, or a pharmaceutically acceptable salt thereof, to a human in need of the intended pharmaceutical activity of such drug, wherein said drug and said CYP2D6 inhibitor are not the same compound.